MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, RAPT had -$3,956K decrease in cash & cash equivalents over the period. -$12,458K in free cash flow.

Cash Flow Overview

Change in Cash
-$3,956K
Free Cash flow
-$12,458K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-17,580 -34,808
Accretion of discounts on marketable securities
735 1,533
Depreciation and amortization
205 480
Stock-based compensation expense
5,029 9,185
Non-cash operating lease expense
478 1,168
Prepaid expenses and other assets
-438 1,615
Accounts payable, accrued expenses and other current liabilities
328 -91
License fees payable
0 -35,000
Operating lease liabilities
-621 -1,471
Net cash used in operating activities
-12,458 -63,685
Purchase of marketable securities
47,743 138,652
Proceeds from maturities of marketable securities
56,209 74,410
Purchase of property and equipment
0 83
Net cash (used in) provided by investing activities
8,466 -64,325
Proceeds from issuances of common stock in 'at-the-market' offerings, net of issuance costs
0 0
Proceeds from issuance of common stock under employee stock plans
36 161
Net cash provided by financing activities
36 161
Net decrease in cash and cash equivalents
-3,956 -127,849
Cash and cash equivalents at beginning of period
169,735 -
Cash and cash equivalents at end of period
37,930 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

RAPT Therapeutics, Inc. (RAPT)

RAPT Therapeutics, Inc. (RAPT)